Previous close | 21.63 |
Open | 21.73 |
Bid | 22.82 x 1000 |
Ask | 22.86 x 800 |
Day's range | 20.80 - 23.42 |
52-week range | 2.43 - 67.00 |
Volume | 11,615,958 |
Avg. volume | 40,180,436 |
Market cap | 3.924B |
Beta (5Y monthly) | 2.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.15 |
Earnings date | 17 Feb 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.32 |
Canadian weed giant Tilray (NASDAQ: TLRY) was on a tear for much of 2020. Investors have a lot to be thrilled about with Tilray, the most promising of which is its substantial international presence, which will become a game-changer as more countries legalize the recreational and medical use of cannabis. Let's investigate how Tilray can capitalize on marijuana's entry to the mainstream.
The Canadian pot stock rose amid a Reddit-fueled rally and positive earnings results from Tilray, which will merge with Aphria next quarter.
Tilray (NASDAQ: TLRY) stock outperformed a rising market last month. Shares soared 35% in February compared to a 2.6% gain in the S&P 500, according to data provided by S&P Global Market Intelligence. Tilray announced positive earnings results last month, with fourth-quarter sales increasing 26% as net loss improved to $3 million from $220 million a year earlier.